Vimirogant (VTP-43742) is a potent, selective, and orally activeRORγtinhibitor (K_i=3.5 nM;IC₅₀=17 nM). Vimirogant exhibits >1000-fold selectivity versus theRORαandRORβisotypes. Vimirogant inhibits Th17 differentiation andIL-17Asecretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research^[1][2].

Vimirogant inhibits the secretion of IL-17A from activated hPBMCs (IC₅₀=18 nM) and human whole blood (IC₅₀=192 nM)^[1].

In the MOG35-55/CFA immunized mouse EAE model, Vimirogant (p.o.) significantly suppresses clinical symptoms, demyelination and mRNA expression of multiple inflammatory markers in the spinal cord^[1].

552.65

C₂₇H₃₅F₃N₄O₃S

1802706-04-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.